Ahmed Adel Mohamed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Adel Mohamed has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Mohammed Dibas
Department of Medicine, Faculty of Medicine and Health Sciences An‐Najah National University Nablus Palestine
2 shared publications Mostafa Elsayed Ahmed
Faculty of Medicine Zagazig University Zagazig Egypt
2 shared publications- Osama M. Aldeeb
Faculty of Medicine The University of Jordan Amman Jordan
2 shared publications - Tasneem Zanati Saeed
Faculty of Medicine Assiut University Assiut Egypt
2 shared publications - Abdallah Al Ghnaimat
Faculty of Medicine, The Hashemite University, Zarqa, Jordan
1 shared publication Abdallah M. Hibysh
Faculty of Medicine New Ismaila National University Ismaila Egypt
1 shared publication
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6)
Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: Polycystic ovary syndrome (PCOS), recently redefined as polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder of reproductive‐age women. Metformin remains first‐line therapy, whereas sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have emerged for their cardiometabolic effects. This study compared SGLT2 inhibitors, alone or with metformin, versus metformin alone in PMOS. Methods: We performed a PRISMA‐guided systematic review and meta‐analysis of randomized controlled trials from PubMed, Scopus, Web of Science, Cochrane CENTRAL and Embase. Two reviewers independently screened, extracted data, assessed risk of bias (Cochrane RoB 2) and rated certainty using GRADE. Continuous outcomes were pooled as mean differences (MD) with 95% confidence intervals (CI) under a random‐effects model; heterogeneity was assessed with I 2 . Results: Five trials (292 women) were included. SGLT2 inhibitors did not differ significantly from metformin in body weight (MD = −2.06 kg; 95% CI −5.79 to 1.68) or BMI (MD = −0.34 kg/m 2 ; 95% CI −0.78 to 0.10), or most hormonal, glycemic and anthropometric outcomes. However, they significantly reduced triglycerides (MD = −0.21 mmol/L; 95% CI −0.38 to −0.05) and diastolic blood pressure (MD = −1.79 mmHg; 95% CI −2.57 to −1.01), with a small increase in systolic blood pressure (MD = 0.97 mmHg; 95% CI 0.11–1.83). Certainty of evidence ranged from low to high. Conclusion: SGLT2 inhibitors, alone or with metformin, did not differ significantly from metformin across most metabolic and endocrine outcomes, with modest benefits on triglycerides and diastolic blood pressure. Metformin remains first‐line therapy; SGLT2 inhibitors may be considered in selected patients pending larger trials.
- 15 November 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6)
Open AccessEfficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: Polycystic ovary syndrome (PCOS), recently redefined as polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder of reproductive‐age women. Metformin remains first‐line therapy, whereas sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have emerged for their cardiometabolic effects. This study compared SGLT2 inhibitors, alone or with metformin, versus metformin alone in PMOS. Methods: We performed a PRISMA‐guided systematic review and meta‐analysis of randomized controlled trials from PubMed, Scopus, Web of Science, Cochrane CENTRAL and Embase. Two reviewers independently screened, extracted data, assessed risk of bias (Cochrane RoB 2) and rated certainty using GRADE. Continuous outcomes were pooled as mean differences (MD) with 95% confidence intervals (CI) under a random‐effects model; heterogeneity was assessed with I 2 . Results: Five trials (292 women) were included. SGLT2 inhibitors did not differ significantly from metformin in body weight (MD = −2.06 kg; 95% CI −5.79 to 1.68) or BMI (MD = −0.34 kg/m 2 ; 95% CI −0.78 to 0.10), or most hormonal, glycemic and anthropometric outcomes. However, they significantly reduced triglycerides (MD = −0.21 mmol/L; 95% CI −0.38 to −0.05) and diastolic blood pressure (MD = −1.79 mmHg; 95% CI −2.57 to −1.01), with a small increase in systolic blood pressure (MD = 0.97 mmHg; 95% CI 0.11–1.83). Certainty of evidence ranged from low to high. Conclusion: SGLT2 inhibitors, alone or with metformin, did not differ significantly from metformin across most metabolic and endocrine outcomes, with modest benefits on triglycerides and diastolic blood pressure. Metformin remains first‐line therapy; SGLT2 inhibitors may be considered in selected patients pending larger trials.
- 26 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Association of MASLD With Atrial Fibrillation Recurrence After Catheter Ablation: A Meta‐Analysis
Background: Atrial fibrillation (AF) recurrence after catheter ablation remains common. Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic condition and has been linked to incident AF, but its association with AF recurrence after catheter ablation remains unclear. This meta‐analysis aimed to determine whether MASLD is associated with recurrent AF after catheter ablation Methods: We searched PubMed, Web of Science, and Scopus till July 2026 for studies that included adults with AF undergoing catheter ablation and compared the risk of AF recurrence between those with and without MASLD. A random‐effects model was used to synthesize HRs and corresponding 95% CIs. Between‐study variability was evaluated with the I 2 measure, with additional subgroup analyses stratified by AF type and MASLD diagnostic method. Results: Six studies comprising 2921 patients (894 with MASLD) were included. MASLD was significantly associated with an increased risk of AF recurrence after ablation (HR 1.91, 95% CI 1.39–2.64; p < 0.001), with substantial heterogeneity ( I 2 = 69.7%). The association remained significant in both paroxysmal (HR 1.78, 95% CI 1.36–2.33) and persistent AF (HR 1.61, 95% CI 1.26–2.05), with no significant subgroup difference ( p = 0.58). Studies using imaging‐based diagnosis of MASLD showed a significant association, whereas the association was not significant when the Fatty Liver Index was used, with no evidence of a difference between diagnostic‐method subgroups ( p = 0.47) Conclusion: MASLD is associated with a higher risk of AF recurrence after catheter ablation and may help identify patients at greater risk of recurrence. Further prospective studies are needed to provide a more comprehensive understanding of this association.
- 26 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Association of MASLD With Atrial Fibrillation Recurrence After Catheter Ablation: A Meta‐Analysis
Background: Atrial fibrillation (AF) recurrence after catheter ablation remains common. Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic condition and has been linked to incident AF, but its association with AF recurrence after catheter ablation remains unclear. This meta‐analysis aimed to determine whether MASLD is associated with recurrent AF after catheter ablation Methods: We searched PubMed, Web of Science, and Scopus till July 2026 for studies that included adults with AF undergoing catheter ablation and compared the risk of AF recurrence between those with and without MASLD. A random‐effects model was used to synthesize HRs and corresponding 95% CIs. Between‐study variability was evaluated with the I 2 measure, with additional subgroup analyses stratified by AF type and MASLD diagnostic method. Results: Six studies comprising 2921 patients (894 with MASLD) were included. MASLD was significantly associated with an increased risk of AF recurrence after ablation (HR 1.91, 95% CI 1.39–2.64; p < 0.001), with substantial heterogeneity ( I 2 = 69.7%). The association remained significant in both paroxysmal (HR 1.78, 95% CI 1.36–2.33) and persistent AF (HR 1.61, 95% CI 1.26–2.05), with no significant subgroup difference ( p = 0.58). Studies using imaging‐based diagnosis of MASLD showed a significant association, whereas the association was not significant when the Fatty Liver Index was used, with no evidence of a difference between diagnostic‐method subgroups ( p = 0.47) Conclusion: MASLD is associated with a higher risk of AF recurrence after catheter ablation and may help identify patients at greater risk of recurrence. Further prospective studies are needed to provide a more comprehensive understanding of this association.
- 20 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (11) , 1762-1771
CRT and CABG Improve Survival and Reduce Readmissions in Ischemic Heart Failure: A Systematic Review and Meta‐Analysis
Introduction: Heart failure (HF) continues to be the leading cause of death and rehospitalization among cardiomyopathic patients undergoing coronary artery bypass grafting (CABG). Objectives: To systematically evaluate the effect of adding cardiac resynchronization therapy (CRT) to CABG versus CABG alone for patients with concomitant ischemic cardiomyopathy and electromechanical dyssynchrony. (PROSPERO ID: CRD420251006918) Methods: A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus to identify clinical trials and cohort studies evaluating the impact of inserting a CRT device during CABG surgery on survival and rehospitalization outcomes. A total of 3 studies involving 300 patients were included: 150 underwent CABG alone, and 150 received both CABG and CRT. Results: The meta‐analysis of two studies ( n = 200) showed that adding CRT during CABG was associated with lowering the probability of HF readmission (RR = 0.25, 95% CI [0.13–0.49], P < 0.0001) and of all‐cause mortality (RR = 0.44, 95% CI [0.25–0.78], p = 0.0048) in the targeted patient population. Analyses according to study design demonstrated consistent treatment effects across randomized and observational evidence, with no significant subgroup differences. Conclusion: In patients with ischemic cardiomyopathy and electromechanical dyssynchrony undergoing CABG, perioperative epicardial CRT implantation may be associated with decreased HF rehospitalization and all‐cause mortality rates. However, given the limited number of included studies and small cumulative sample size, these findings should be considered hypothesis‐generating, and large‐scale confirmatory randomized trials are warranted. Registration: The study protocol was prospectively registered in PROSPERO. (CRID: CRD420251006918).
- 20 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (11) , 1762-1771
CRT and CABG Improve Survival and Reduce Readmissions in Ischemic Heart Failure: A Systematic Review and Meta‐Analysis
Introduction: Heart failure (HF) continues to be the leading cause of death and rehospitalization among cardiomyopathic patients undergoing coronary artery bypass grafting (CABG). Objectives: To systematically evaluate the effect of adding cardiac resynchronization therapy (CRT) to CABG versus CABG alone for patients with concomitant ischemic cardiomyopathy and electromechanical dyssynchrony. (PROSPERO ID: CRD420251006918) Methods: A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus to identify clinical trials and cohort studies evaluating the impact of inserting a CRT device during CABG surgery on survival and rehospitalization outcomes. A total of 3 studies involving 300 patients were included: 150 underwent CABG alone, and 150 received both CABG and CRT. Results: The meta‐analysis of two studies ( n = 200) showed that adding CRT during CABG was associated with lowering the probability of HF readmission (RR = 0.25, 95% CI [0.13–0.49], P < 0.0001) and of all‐cause mortality (RR = 0.44, 95% CI [0.25–0.78], p = 0.0048) in the targeted patient population. Analyses according to study design demonstrated consistent treatment effects across randomized and observational evidence, with no significant subgroup differences. Conclusion: In patients with ischemic cardiomyopathy and electromechanical dyssynchrony undergoing CABG, perioperative epicardial CRT implantation may be associated with decreased HF rehospitalization and all‐cause mortality rates. However, given the limited number of included studies and small cumulative sample size, these findings should be considered hypothesis‐generating, and large‐scale confirmatory randomized trials are warranted. Registration: The study protocol was prospectively registered in PROSPERO. (CRID: CRD420251006918).
- 10 July 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (8) , 201
Patient overlap and the validity of SGLT2 inhibitor benefits after TAVI: a critique of recent meta-analytical findings
- 10 July 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (8) , 201
Patient overlap and the validity of SGLT2 inhibitor benefits after TAVI: a critique of recent meta-analytical findings
- Open Access
- 4 July 2026
- Published by Springer Nature in BMC Sports Science, Medicine and Rehabilitation
- Vol. 18 (1)
Comparative effects of pilates-based interventions on functional mobility, balance, fatigue, and quality of life in people with multiple sclerosis: a systematic review and network meta-analysis
Purpose: Pilates-based exercise has gained attention as a non-pharmacological rehabilitation strategy for people with multiple sclerosis (MS), yet the comparative effectiveness of different Pilates modalities remains uncertain. This systematic review and network meta-analysis evaluated and ranked Pilates-based interventions for functional mobility, balance, walking performance, fatigue, and health-related quality of life in adults with MS. Methods: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched from inception to October 24, 2025. Eligible studies were randomized controlled trials of structured Pilates-based interventions lasting at least four weeks in adults with MS. The primary outcome was functional mobility measured by the Timed Up and Go test. Secondary outcomes included balance, walking endurance, fatigue, walking performance, and MS-specific quality of life. A frequentist random-effects network meta-analysis was performed; treatment ranking was summarized using SUCRA, risk of bias using RoB 2, and certainty of evidence using GRADE-NMA through CINeMA. Results: Twenty-two randomized controlled trials involving 901 participants were included. Pilates ranked first for functional mobility and significantly improved Timed Up and Go performance versus control (MD: -5.23 s; 95% CI: -6.39 to -4.06). It also ranked first for balance, with a mean improvement of 8.58 points on the Berg Balance Scale (95% CI: 7.86 to 9.30). Pilates combined with Pilates-based telerehabilitation ranked highest for the 6-Minute Walk Test (MD: 50.81 m; 95% CI: 0.16 to 101.46) and significantly improved Fatigue Severity Scale scores. Home-based Pilates showed the largest reduction in Modified Fatigue Impact Scale scores. No comparison reached high certainty under GRADE-NMA. Conclusion: Pilates-based interventions may improve mobility, balance, walking endurance, fatigue, and quality of life in people with MS. Sparse networks, risk of bias, heterogeneity, imprecision, and limited follow-up warrant cautious interpretation. Adequately powered trials with standardized protocols are needed before routine implementation can be recommended.
- 4 July 2026
- Published by Springer Nature in BMC Sports Science, Medicine and Rehabilitation
- Vol. 18 (1)
Open AccessComparative effects of pilates-based interventions on functional mobility, balance, fatigue, and quality of life in people with multiple sclerosis: a systematic review and network meta-analysis
Purpose: Pilates-based exercise has gained attention as a non-pharmacological rehabilitation strategy for people with multiple sclerosis (MS), yet the comparative effectiveness of different Pilates modalities remains uncertain. This systematic review and network meta-analysis evaluated and ranked Pilates-based interventions for functional mobility, balance, walking performance, fatigue, and health-related quality of life in adults with MS. Methods: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched from inception to October 24, 2025. Eligible studies were randomized controlled trials of structured Pilates-based interventions lasting at least four weeks in adults with MS. The primary outcome was functional mobility measured by the Timed Up and Go test. Secondary outcomes included balance, walking endurance, fatigue, walking performance, and MS-specific quality of life. A frequentist random-effects network meta-analysis was performed; treatment ranking was summarized using SUCRA, risk of bias using RoB 2, and certainty of evidence using GRADE-NMA through CINeMA. Results: Twenty-two randomized controlled trials involving 901 participants were included. Pilates ranked first for functional mobility and significantly improved Timed Up and Go performance versus control (MD: -5.23 s; 95% CI: -6.39 to -4.06). It also ranked first for balance, with a mean improvement of 8.58 points on the Berg Balance Scale (95% CI: 7.86 to 9.30). Pilates combined with Pilates-based telerehabilitation ranked highest for the 6-Minute Walk Test (MD: 50.81 m; 95% CI: 0.16 to 101.46) and significantly improved Fatigue Severity Scale scores. Home-based Pilates showed the largest reduction in Modified Fatigue Impact Scale scores. No comparison reached high certainty under GRADE-NMA. Conclusion: Pilates-based interventions may improve mobility, balance, walking endurance, fatigue, and quality of life in people with MS. Sparse networks, risk of bias, heterogeneity, imprecision, and limited follow-up warrant cautious interpretation. Adequately powered trials with standardized protocols are needed before routine implementation can be recommended.
- Open Access
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Association of Sodium–Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE‐Assessed Meta‐Analysis
Background: Patients undergoing transcatheter aortic valve implantation (TAVI) remain at risk of adverse cardiovascular and renal outcomes despite procedural advancements. Sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiovascular and renal benefits across various patient populations; however, their role in patients undergoing TAVI remains unclear. This study is aimed at evaluating the association between SGLT2 inhibitor use and clinical outcomes in this population. Methods: We conducted a systematic review and meta‐analysis comparing SGLT2 inhibitors versus non‐SGLT2 inhibitors or standard care in patients undergoing TAVI. Major databases were searched through March 2026, with Embase updated through June 2026. Pooled analyses were performed using random‐effects models to calculate risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). Results: Five studies involving 6111 patients (SGLT2 inhibitors: n = 2933; control: n = 3178) were included. In primary random‐effects models, SGLT2 inhibitors were associated with lower all‐cause mortality (RR 0.68, 95% CI 0.48–0.97, p = 0.03), heart failure (HF) hospitalization (RR 0.62, 95% CI 0.42–0.90, p = 0.01), and major adverse cardiovascular events (RR 0.68, 95% CI 0.48–0.96, p = 0.03). However, in REML/Hartung–Knapp sensitivity analyses, CIs crossed the null for all‐cause mortality, HF hospitalization, MACE, and pooled hazard ratios. Mortality benefits were absent at 6 and 12 months and in the randomized trial but persisted in low left ventricular ejection fraction (RR 0.56, 95% CI 0.35–0.89, p = 0.01). No significant differences occurred in acute kidney injury, urinary tract infections, or echocardiographic parameters. Conclusion: SGLT2 inhibitor use was associated with lower all‐cause mortality and HF hospitalization after TAVI, but the evidence is limited by observational designs, heterogeneity, and low certainty for several outcomes. Further randomized trials are required.
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Open AccessAssociation of Sodium–Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE‐Assessed Meta‐Analysis
Background: Patients undergoing transcatheter aortic valve implantation (TAVI) remain at risk of adverse cardiovascular and renal outcomes despite procedural advancements. Sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiovascular and renal benefits across various patient populations; however, their role in patients undergoing TAVI remains unclear. This study is aimed at evaluating the association between SGLT2 inhibitor use and clinical outcomes in this population. Methods: We conducted a systematic review and meta‐analysis comparing SGLT2 inhibitors versus non‐SGLT2 inhibitors or standard care in patients undergoing TAVI. Major databases were searched through March 2026, with Embase updated through June 2026. Pooled analyses were performed using random‐effects models to calculate risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). Results: Five studies involving 6111 patients (SGLT2 inhibitors: n = 2933; control: n = 3178) were included. In primary random‐effects models, SGLT2 inhibitors were associated with lower all‐cause mortality (RR 0.68, 95% CI 0.48–0.97, p = 0.03), heart failure (HF) hospitalization (RR 0.62, 95% CI 0.42–0.90, p = 0.01), and major adverse cardiovascular events (RR 0.68, 95% CI 0.48–0.96, p = 0.03). However, in REML/Hartung–Knapp sensitivity analyses, CIs crossed the null for all‐cause mortality, HF hospitalization, MACE, and pooled hazard ratios. Mortality benefits were absent at 6 and 12 months and in the randomized trial but persisted in low left ventricular ejection fraction (RR 0.56, 95% CI 0.35–0.89, p = 0.01). No significant differences occurred in acute kidney injury, urinary tract infections, or echocardiographic parameters. Conclusion: SGLT2 inhibitor use was associated with lower all‐cause mortality and HF hospitalization after TAVI, but the evidence is limited by observational designs, heterogeneity, and low certainty for several outcomes. Further randomized trials are required.